Jennifer Soriano LeBovidge, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dermatitis, Atopic | 17 | 2023 | 729 | 2.580 |
Why?
|
Eczema | 9 | 2023 | 246 | 1.830 |
Why?
|
Food Hypersensitivity | 7 | 2024 | 737 | 1.470 |
Why?
|
Patient Education as Topic | 5 | 2021 | 2334 | 0.780 |
Why?
|
Caregivers | 5 | 2023 | 2307 | 0.520 |
Why?
|
Teaching Materials | 1 | 2016 | 85 | 0.500 |
Why?
|
Allergens | 8 | 2022 | 1436 | 0.470 |
Why?
|
Pruritus | 5 | 2023 | 378 | 0.440 |
Why?
|
Desensitization, Immunologic | 5 | 2022 | 544 | 0.380 |
Why?
|
Anti-Allergic Agents | 3 | 2018 | 153 | 0.360 |
Why?
|
Arthritis | 3 | 2005 | 677 | 0.340 |
Why?
|
Peanut Hypersensitivity | 3 | 2018 | 217 | 0.320 |
Why?
|
Attitude to Health | 3 | 2008 | 2020 | 0.310 |
Why?
|
Asthma | 5 | 2023 | 6270 | 0.280 |
Why?
|
Patient-Centered Care | 1 | 2017 | 1458 | 0.280 |
Why?
|
Patient Care Team | 1 | 2016 | 2517 | 0.240 |
Why?
|
Quality of Life | 12 | 2024 | 13462 | 0.230 |
Why?
|
Hypersensitivity | 2 | 2023 | 1168 | 0.220 |
Why?
|
Decision Making | 1 | 2017 | 3965 | 0.220 |
Why?
|
Parents | 2 | 2008 | 3592 | 0.210 |
Why?
|
Egg Hypersensitivity | 1 | 2022 | 47 | 0.200 |
Why?
|
Stress, Psychological | 2 | 2009 | 4533 | 0.190 |
Why?
|
Milk Hypersensitivity | 1 | 2022 | 83 | 0.190 |
Why?
|
Parent-Child Relations | 1 | 2006 | 774 | 0.180 |
Why?
|
Adaptation, Psychological | 4 | 2008 | 2660 | 0.180 |
Why?
|
Health Services Accessibility | 1 | 2017 | 5508 | 0.170 |
Why?
|
Life Change Events | 1 | 2005 | 954 | 0.160 |
Why?
|
Dermatologic Agents | 1 | 2023 | 315 | 0.160 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2006 | 953 | 0.150 |
Why?
|
Anxiety Disorders | 1 | 2009 | 2737 | 0.150 |
Why?
|
Skin Diseases, Infectious | 1 | 2017 | 73 | 0.140 |
Why?
|
Child | 19 | 2024 | 80564 | 0.140 |
Why?
|
Capital Financing | 1 | 2016 | 58 | 0.130 |
Why?
|
Dermatitis, Allergic Contact | 1 | 2017 | 112 | 0.130 |
Why?
|
Health Promotion | 1 | 2006 | 2208 | 0.120 |
Why?
|
Anti-Infective Agents | 1 | 2022 | 986 | 0.120 |
Why?
|
Histamine Antagonists | 1 | 2014 | 93 | 0.110 |
Why?
|
Complementary Therapies | 1 | 2017 | 487 | 0.110 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 4 | 1999 | 3719 | 0.110 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2022 | 1090 | 0.100 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2013 | 340 | 0.100 |
Why?
|
Humans | 36 | 2024 | 765968 | 0.090 |
Why?
|
Adrenal Cortex Hormones | 2 | 2023 | 1880 | 0.090 |
Why?
|
Pemoline | 1 | 1999 | 18 | 0.080 |
Why?
|
Accidents | 1 | 2010 | 164 | 0.080 |
Why?
|
Immunoglobulin E | 3 | 2022 | 1481 | 0.080 |
Why?
|
Child, Preschool | 5 | 2016 | 42500 | 0.080 |
Why?
|
Family Relations | 1 | 2010 | 318 | 0.080 |
Why?
|
Self Concept | 2 | 2003 | 1037 | 0.080 |
Why?
|
Disease Management | 2 | 2016 | 2535 | 0.070 |
Why?
|
Isoxazoles | 1 | 1999 | 234 | 0.070 |
Why?
|
Pyrrolidines | 1 | 1999 | 337 | 0.070 |
Why?
|
Adolescent | 13 | 2023 | 88835 | 0.070 |
Why?
|
Anti-Anxiety Agents | 1 | 1999 | 402 | 0.070 |
Why?
|
Health Care Reform | 1 | 2016 | 1259 | 0.070 |
Why?
|
Depression | 1 | 2006 | 8237 | 0.070 |
Why?
|
Health Personnel | 2 | 2016 | 3390 | 0.060 |
Why?
|
Trichotillomania | 1 | 1996 | 178 | 0.050 |
Why?
|
Patient Satisfaction | 1 | 2016 | 3475 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5526 | 0.050 |
Why?
|
Male | 16 | 2023 | 363698 | 0.050 |
Why?
|
Dermatophagoides pteronyssinus | 1 | 2022 | 11 | 0.050 |
Why?
|
Defense Mechanisms | 1 | 2003 | 178 | 0.050 |
Why?
|
Female | 16 | 2023 | 396112 | 0.050 |
Why?
|
Pyroglyphidae | 1 | 2022 | 94 | 0.050 |
Why?
|
Baths | 1 | 2022 | 52 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2016 | 4058 | 0.050 |
Why?
|
Central Nervous System Stimulants | 1 | 1999 | 1167 | 0.040 |
Why?
|
Infant | 3 | 2022 | 36386 | 0.040 |
Why?
|
Cost of Illness | 2 | 2017 | 1950 | 0.040 |
Why?
|
Cooking | 1 | 2022 | 327 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2016 | 22223 | 0.040 |
Why?
|
Milk | 1 | 2022 | 436 | 0.040 |
Why?
|
Tacrolimus | 1 | 2023 | 753 | 0.040 |
Why?
|
Young Adult | 3 | 2022 | 59889 | 0.040 |
Why?
|
Chronic Disease | 2 | 2005 | 9347 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5370 | 0.040 |
Why?
|
Health Surveys | 1 | 2008 | 4056 | 0.040 |
Why?
|
Administration, Oral | 2 | 2018 | 4015 | 0.040 |
Why?
|
Wounds and Injuries | 1 | 2010 | 2511 | 0.040 |
Why?
|
Family | 1 | 2008 | 3209 | 0.040 |
Why?
|
Prevalence | 2 | 2024 | 15842 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2023 | 10383 | 0.030 |
Why?
|
Rheumatic Diseases | 1 | 2002 | 622 | 0.030 |
Why?
|
Severity of Illness Index | 3 | 2011 | 15880 | 0.030 |
Why?
|
Skin Tests | 1 | 2016 | 630 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2016 | 39193 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2022 | 2354 | 0.030 |
Why?
|
Bipolar Disorder | 2 | 1998 | 5138 | 0.030 |
Why?
|
Staphylococcus aureus | 1 | 2022 | 1424 | 0.030 |
Why?
|
Double-Blind Method | 3 | 2016 | 12437 | 0.030 |
Why?
|
Massachusetts | 1 | 2006 | 8875 | 0.030 |
Why?
|
Adult | 9 | 2024 | 223044 | 0.030 |
Why?
|
Cross-Over Studies | 2 | 1999 | 2108 | 0.030 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2010 | 4628 | 0.030 |
Why?
|
Population Groups | 1 | 2013 | 209 | 0.030 |
Why?
|
Treatment Outcome | 5 | 2023 | 65188 | 0.020 |
Why?
|
Administration, Topical | 1 | 2014 | 704 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2023 | 4209 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 1997 | 4416 | 0.020 |
Why?
|
Cholinergic Agonists | 1 | 1999 | 75 | 0.020 |
Why?
|
Regression Analysis | 2 | 2010 | 6322 | 0.020 |
Why?
|
Mental Health | 1 | 2023 | 3278 | 0.020 |
Why?
|
Health Status | 1 | 2002 | 4080 | 0.020 |
Why?
|
Comorbidity | 2 | 2017 | 10563 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2017 | 12976 | 0.020 |
Why?
|
Pilot Projects | 2 | 2013 | 8733 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 1999 | 715 | 0.020 |
Why?
|
Patient Care | 1 | 2013 | 629 | 0.020 |
Why?
|
Nausea | 1 | 1999 | 680 | 0.020 |
Why?
|
Dizziness | 1 | 1999 | 269 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 8529 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2013 | 3537 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2023 | 7478 | 0.010 |
Why?
|
Marital Status | 1 | 1996 | 426 | 0.010 |
Why?
|
Diet | 1 | 2022 | 8086 | 0.010 |
Why?
|
Animals | 3 | 2022 | 168764 | 0.010 |
Why?
|
Skin | 1 | 2017 | 4489 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2010 | 2739 | 0.010 |
Why?
|
Personality Inventory | 1 | 1996 | 1018 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2014 | 3685 | 0.010 |
Why?
|
Family Health | 1 | 1997 | 1253 | 0.010 |
Why?
|
Child Behavior Disorders | 1 | 1997 | 814 | 0.010 |
Why?
|
Risk | 1 | 2013 | 9591 | 0.010 |
Why?
|
Body Image | 1 | 1996 | 644 | 0.010 |
Why?
|
Probability | 1 | 1996 | 2475 | 0.010 |
Why?
|
United States | 2 | 2023 | 72903 | 0.010 |
Why?
|
Psychometrics | 1 | 1998 | 3062 | 0.010 |
Why?
|
Age of Onset | 1 | 1996 | 3344 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 1998 | 6014 | 0.010 |
Why?
|
Educational Status | 1 | 1996 | 2513 | 0.010 |
Why?
|
Boston | 1 | 2010 | 9338 | 0.010 |
Why?
|
Health Status Indicators | 1 | 2002 | 966 | 0.010 |
Why?
|
Time Factors | 1 | 2018 | 40065 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 7425 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2005 | 81514 | 0.010 |
Why?
|
Age Factors | 1 | 1999 | 18380 | 0.010 |
Why?
|
Sex Factors | 1 | 1996 | 10603 | 0.010 |
Why?
|
Prognosis | 1 | 2011 | 29922 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2010 | 26318 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 1998 | 18071 | 0.000 |
Why?
|
Cohort Studies | 1 | 1997 | 41649 | 0.000 |
Why?
|
Risk Factors | 1 | 1998 | 74840 | 0.000 |
Why?
|
Middle Aged | 1 | 1999 | 223009 | 0.000 |
Why?
|